Piramal Pharma Ltd
Piramal Pharma Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Q4 is expected to show sequential revenue growth compared to Q3, but no year-on-year Q4 versus Q4 growth due to a strong large order last year. FY '26 is muted due to inventory destocking, slower U.S.
From Piramal Pharma Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Q4 is expected to show sequential revenue growth compared to Q3, but no year-on-year Q4 versus Q4 growth due to a strong large order last year.
- CDMO business (excluding inventory destocking) is growing in low single digits, with expectations for continued growth driven by improved biotech funding and new client additions.
- Overseas CDMO facilities with high gross margin profiles are anticipated to enhance margins as capacity utilization improves.
- The consumer products business, now breakeven, is expected to expand margins and grow further.
- The Kenalog acquisition (annualized sales $30-$40 million) adds a stable, near-to-medium-term contributor, fitting strategically with existing portfolio and sales capabilities.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Piramal Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Average CAPEX spend is between $70 million to $100 million annually.
- Higher CAPEX expected in the near term due to major expansions at Lexington and Riverview facilities.
- Lexington expansion is underway, with commissioning expected by end of Calendar Year 2027.
- Riverview facility's linker payload expansion is nearly ready and expected to come online this quarter.
- Investments are aligned with long-term plans and payback metrics for CDMO and Complex Hospital Generics (CHG) businesses.
- Consumer products business is self-funding and does not require external capital infusion.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Piramal Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has a large Phase-3 pipeline with over 30 products, with programs primarily in oncology, metabolic diseases, and rare diseases.
- Order booking saw an improvement in Q3 FY '26, serving as a leading indicator of client ability to fund and spend on CDMO services.
- Since October 2025, there has been a significant increase in RFPs (Request for Proposals), especially for U.S. facilities, indicating growing demand.
- Typical lead time from proposal to client decision is around 180 days.
- There is cautious optimism about translating these RFPs into confirmed orders over the next 180 days.
- The impact of inventory destocking on order volumes is expected to normalize, with underlying portfolio growth in low single digits excluding destocking effects.
2 more points management made on order book & pipeline
Piramal Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.8K Cr, net loss ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Piramal Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Piramal Pharma Ltd Q3 FY26 results?
Q4 is expected to show sequential revenue growth compared to Q3, but no year-on-year Q4 versus Q4 growth due to a strong large order last year. FY '26 is muted due to inventory destocking, slower U.S.
What is Piramal Pharma Ltd share price analysis?
Piramal Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹27,530 Cr. Investors should review the full earnings analysis for detailed insights.
Is Piramal Pharma Ltd planning capital expenditure?
Average CAPEX spend is between $70 million to $100 million annually.
Keep Piramal Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.